Quantum Biopharma Moves Forward in Lucid-MS Clinical Trial

Quantum Biopharma Ltd., a biopharmaceutical firm listed on NASDAQ, CSE, and FRA, announced a pivotal advancement in its clinical trial of Lucid-21-302. The safety review committee endorsed the initiation of the second cohort in the Phase 1 study, following an analysis of data from the initial group. The trial, a randomized, double-blind, placebo-controlled study, aims to assess the safety and pharmacokinetics of Lucid-21-302 in healthy adults.

Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs, expressed satisfaction with the trial's progress and readiness to proceed with the next phase in the coming days. This development marks a key step in Quantum Biopharma's efforts to advance treatments for neurodegenerative disorders, with Lucid-MS showing promise in preclinical models for multiple sclerosis.